1417526-55-6

Basic information

• Product Name: 2-(hydroxymethyl)-1-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazole-5-carbaldehyde
• Synonyms: 2-(hydroxymethyl)-1-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazole-5-carbaldehyde
• CAS NO: 1417526-55-6
• Molecular Weight: 360.336
• Mol File: 1417526-55-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(hydroxymethyl)-1-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazole-5-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(hydroxymethyl)-1-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazole-5-carbaldehyde(1417526-55-6)
• EPA Substance Registry System: 2-(hydroxymethyl)-1-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazole-5-carbaldehyde(1417526-55-6)

Safety Data

• Hazardous Substances Data: 1417526-55-6(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 312936-81-5 1-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazole-5-carbaldehyde 
• 312936-77-9 1-(4-Bromobenzyl)-2-Mercapto-5-Hydroxymethylimidazole 
• 106-40-1 4-bromo-aniline 
• 220364-22-7 1-(4-Bromobenzyl)-5-hydroxymethyl-1H-imidazole 
• 312936-79-1 (1-((4’-(trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazol-5-yl)methanol 

Downstream Products

• 1432488-16-8 C₃₃H₃₉F₃N₆OS 
• 1417526-57-8 (5-((4-benzylpiperazin-1-yl)methyl)-1-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazol-2-yl)methanol 
• 1417526-58-9 (5-((dimethylamino)methyl)-1-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazol-2-yl)methanol 

Relevant articles and documents

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

The present invention relates to the filed of pharmarcutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) amd a preparation method thereof, a pharmarcutical composition with the compounds as active components, and a use of the azole compounds and the pharmarcutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as deinfed in the specifictaion.

Triazole derivatives: A series of Darapladib analogues as orally active Lp-PLA2 inhibitors

This Letter reports our efforts towards the optimization of our previously identified series of imidazole and triazole derivatives that lead to the discovery of a series of orally active Lp-PLA2 inhibitors in C57 mice. These inhibitors are characterized by the presence of a diamine side chain in the molecules, such as 2c, 2f, and 4a. The introduction of the terminal-end amine succeeded in maintaining the in vitro activities at sub-nanomolar levels. The vivo activities could be greatly affected by variations in the two amines via modulating the metabolic stability and lipophilicity of the compounds.